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Background: The dried root of Paeonia lactiflora Pall. (PLP) is a classical Chinese herbal
medicine that has been used to treat hepatic disease for 1000s of years. Our previous
work suggested that PLP can be used to treat hepatitis with severe cholestasis. This
study explored the mechanism by which PLP affects ANIT-induced cholestasis in rats
using a metabolomics approach.
Methods: The effects of PLP on serum indices (TBIL, DBIL, AST, ALT, ALP, and
TBA) and the histopathology of the liver were analyzed. Moreover, UHPLC-Q-TOF was
performed to identify the possible effect of PLP on metabolites. The pathway analysis
was conducted to illustrate the pathways and network by which PLP treats cholestasis.
Result: High-dose PLP remarkably down-regulated the serum indices and alleviated
histological damage to the liver. Metabolomics analyses showed that the therapeutic
effect of high-dose PLP is mainly associated with the regulation of several metabolites,
such as glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, L(D)-arginine,
and L-tryptophan. A pathway analysis showed that the metabolites were related to
bile acid secretion and amino acid metabolism. In addition, the significant changes
in bile acid transporters also indicated that bile acid metabolism might be involved in
the therapeutic effect of PLP on cholestasis. Moreover, a principal component analysis
indicated that the metabolites in the high-dose PLP group were closer to those of the
control, whereas those of the moderate dose or low-dose PLP group were closer to
those of the ANIT group. This finding indicated that metabolites may be responsible for
the differences between the effects of low-dose and moderate-dose PLP.
Conclusion: The therapeutic effect of high-dose PLP on cholestasis is possibly related
to regulation of bile acid secretion and amino acid metabolism. Moreover, these findings
may help better understand the mechanisms of disease and provide a potential therapy
for cholestasis.
Keywords: Paeonia lactiflora Pall., cholestasis, metabolomics, bile acid secretion, biomarker
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INTRODUCTION
Cholestasis is a widespread disease that aﬄicts people worldwide
due to its high morbidity. According to the reports from Centers
for Disease Control, cholestasis is one of the top 15 causes
of death in the United States (Yang et al., 2009). In China,
this disease heavily burdens patients and society (Ma et al.,
2014). Cholestasis is characterized by decreased bile ﬂow and
the concurrent accumulation of bile acids and is observed in a
variety of hereditary and acquired liver diseases. It is one of the
most common and devastatingmanifestations of liver disease and
invariably is accompanied by a pool of outcomes without proper
treatment, such as hepatic failure and cirrhosis (Zhao et al., 2013).
It frequently occurs due to various endogenous and exogenous
factors, but the progression of the disease seems to be similar
(Delemos and Friedman, 2013). Oxidative stress, inﬂammation
and the dysregulation of transporters are commonly thought
to be the crucial pathological mechanism responsible for the
development of this disease (Beuers et al., 2015). Moreover,
recent metabolomics studies revealed that abnormal changes in
antioxidative and cytoprotective metabolites as well as bile acids
are also involved in this progression (Aoki et al., 2011; Beyog˘lu
and Idle, 2013).
Traditional Chinese medicine has been practiced in China
for 1000s of years, and its application in the prevention and
treatment of cholestasis has garnered increasing attention (Zhang
et al., 2013; Chen et al., 2015b). The dried root of PLP
[Paeonia species (Fam. Ranunculaceae), Chishao in Chinese],
initially recorded in Shen Nong’s Chinese Materia Medica, has
traditionally been used to reduce fever, eliminate stasis, activate
blood circulation, and relieve pain based on the theory of
TCM. In modern research, growing evidence indicates that
PLP markedly aﬀects liver diseases, such as acute liver injury,
cholestatic hepatitis, and liver ﬁbrosis (Li et al., 2011; Zhao
et al., 2014, 2015). In our previous meta-analysis, high-dose
PLP was eﬀective in treating severe cholestasis (Ma et al., 2014).
However, compared with studies of its clinical application and
pharmacological eﬀect, studies of the mechanism by which PLP
alleviates cholestasis have been inadequate.
As a crucial component of systems biology, metabolomics
depicts the whole metabolic proﬁle by detecting 1000s of
molecules in various biological ﬂuids, such as the urine, saliva,
and blood (Griﬃn, 2006). By analyzing speciﬁc early biomarkers
during disease or drug treatment, metabolomics provides holistic
insight into the relationship between a substance and metabolic
pathways (Wang et al., 2011; Sun et al., 2012). Moreover, many
studies revealed that metabolomics has increased the impetus to
apply traditional medicine research in recent years (Cao et al.,
2015). The Yinchenhao decoction, a famous Chinese formula
Abbreviations: ANIT, alpha-naphthylisothiocyanate; ALP, alkaline phosphatase;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSEP, bile salt
export pump; DBIL, direct bilirubin; MRP2, multidrug resistance-associated
protein 2; NTCP, Na+/taurocholate cotransporting polypeptide; PCA, principal
component analysis; PLP, Paeonia lactiﬂora Pall.; PLS-DA, partial least-squares
discriminant analysis; Q-TOF, quadruple-time-of-ﬂight; TBA, total bile acid; TBIL,
total bilirubin; TCM, traditional Chinese medicine; UDCA, ursodeoxycholic acid;
UHPLC, ultra high performance liquid chromatography.
for treating jaundice, has been proven eﬀective in alleviating
perturbations in multiple pathways in a jaundice model by a
metabolomics analysis (Sun et al., 2014). Additionally,Muntingia
calabura L., commonly used as a liver tonic in Southeast Asia,
has been demonstrated to protect against CCl4-induced liver
injury by aﬀecting the biosynthesis of primary bile acid and
metabolism of arachidonic acid, two major pathways, using an
LC–MSmetabolomics approach (Roﬁee et al., 2015).
In this study, we performed a metabolomics assay using
UHPLC coupled with Q-TOF mass spectrometry to characterize
the metabolic proﬁles resulting from the eﬀect of PLP on
cholestasis. Furthermore, to deeply characterize this mechanism
as a function of PLP dose, a systematic analysis of speciﬁc
biomarkers and the unique biochemical pathways was conducted
with multivariate data analysis techniques, which might provide
novel insight into improving the treatment of cholestatic liver
injury.
MATERIALS AND METHODS
Water Extract of PLP Preparation
Paeonia lactiﬂora Pall. was purchased from Lvye, Co., Ltd.
(Beijing, China). The origin and quality of PLP were identiﬁed
according to the Chinese pharmacopeia (2015 Edition). A water
extract of PLP was prepared by extracting the dried plant twice
with water (2 h for the ﬁrst extraction, 1.5 h for the second
extraction). The extract was then decanted, ﬁltered through six-
layer gauze and evaporated to dry under reduced pressure. The
ﬁnal ratio of powder to raw herb was 25.8%. The extract was
chemically characterized by LC–MS, and themain components in
the water extract of PLPwere identiﬁed as paeoniﬂorin, albiﬂorin,
oxypaeoniﬂorin, and benzoylpaeoniﬂorin in our previous study
(Ma et al., 2015).
Animal Handling and Sample Preparation
Animal Handling
Male Sprague-Dawley rats weighing 200 ± 20 g were obtained
from the laboratory animal center of the Military Medical Science
Academy of the PLA [Permission No. SCXK-(A) 2012-0004].
All animals were allowed to acclimate for 1 week prior to the
experiment and were kept at the same temperature (25 ± 2◦C)
and lighting (12:12 h light:dark cycle) conditions. Water and food
were available to rats ad libitum. All studies were performed in
accordance with the Guiding Principles for the Care and Use
of Laboratory Animals of China. The animals were randomly
divided into six groups of six rats each. The PLP water extract
was dissolved in normal saline and intragastrically administered
to rats at doses of 80, 40, or 20 g/kg·days for 5 days. Rats in the
PLP groups intragastrically received 60 mg/kg ANIT (dissolved
in olive oil) on the third day. The ANIT group received normal
saline each day and was compared with the PLP groups. On the
third day, the ANIT group was also treated with 60 mg/kg ANIT.
The rats serving as a control received normal saline each day and
intragastric treatment with the vehicle (olive oil) alone. UDCA,
the positive control, was given to rats at dose of 60 mg/kg·days
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for 5 days using the same conditions used for the PLP or ANIT
groups (Zhao et al., 2015).
Sample Preparation
The rats were sacriﬁced after the last treatment. Blood samples
were collected and centrifuged at 3000 × g for 10 min to
obtain serum. All serum samples were sterile, hemolysis-free and
stored at −70◦C before determining the biochemical parameters
and conducting the metabolomics analysis. The serum levels of
ALT, AST, TBIL, DBIL, TBA, and ALP were measured on a
Synergy hybrid reader (Biotek, Winooski, VT, USA). The livers
were excised and ﬁxed in 10% PBS-buﬀered formalin. Three or
four paraﬃn-embedded sections (4–5 μm thick) per specimen
were prepared and stained with hematoxylin-eosin (HE staining).
The stained sections were examined under a Nikon microscope
(Tokyo, Japan) and analyzed using the image Pro-Plus 7200
software.
Western Blotting
Liver tissue (0.1 g) was homogenized and subsequently lysed
in ice-cold lysis buﬀer containing 1 mM phenylmethylsulfonyl
ﬂuoride and a protease inhibitor mixture. The sample was
centrifuged at 8000× g and 4◦C for 10 min to remove any debris.
After centrifugation, the supernatant was aliquoted and stored
at −80◦C for the western blotting assay to detect BSEP, NTCP,
and MRP2. Fifty micrograms of total liver protein was separated
by 12% SDS-polyacrylamide gel electrophoresis and transferred
to a nitrocellulose membrane. Immunodetection was performed
using rabbit anti-BSEP antibody (1:1000), anti-NTCP antibody
(1:1000), anti-MRP2 antibody (1:1000), and anti-beta ACTIN
antibody (1:1000) in a solution of 5% milk in Tris-buﬀered saline
and 0.05% Tween-20. After incubation with the appropriate
secondary peroxidase-conjugated antibody, the membrane was
washed in TBST for 60 min, and the immunoreactive bands were
visualized with chemiluminescence.
Metabolic Profiling
Injection Sample Handling
Two hundred microliters of thawed serum samples and 600μL of
methanol were transferred to a 1.5 mL polypropylene tube, and
the solution was then mixed and allowed to stand for 20 min at
4◦C before use. The samples were collected after centrifugation at
12,000 rpm and 4◦C for 10 min to remove any solid debris. The
supernatant was transferred to a polypropylene tube and then
ﬁltered through a syringe ﬁlter (0.22 μm) to obtain the injection
samples.
Chromatography
Chromatography was performed using an Agilent 1290 series
UHPLC system (Agilent Technologies, Santa Clara, CA, USA)
equipped with quaternary pump, online degasser, autosampler,
and thermostatted column compartment. The volume of
injection samples was ﬁxed at 4 μL. All samples were maintained
at 4◦C during the analysis. The separation was performed on
a ZORBAX RRHD 300 SB-C18 column (2.1 mm × 100 mm,
1.8 μm, Agilent Technologies, Santa Clara, CA, USA). The
column temperature was set to 30◦C. The mobile phases
consisted of 0.1% formic acid in acetonitrile (solvent A) and
0.1% formic acid in water (solvent B). The ﬂow rate was set to
0.30 mL/min. The following gradient was used: a linear gradient
of 95% A for the ﬁrst minute, 95–60% A from 1.0 to 9.0 min, 60–
10% A from 9.0 to 19.0 min, 10–0% A from 19.0 to 21.0 min, and
0%A from 21.0 to 25.0 min. The eluent was directly introduced to
the mass spectrometer. After the injection of 10 samples, a pooled
sample, the QC sample, followed by a blank was injected in order
to ensure the stability and repeatability of the LC–MS systems.
Mass Spectrometry
For mass spectrometry, an Agilent 6550 Q-TOF/MS instrument
(Agilent Technologies, Santa Clara, CA, USA) with an
electrospray ionization source (ESI) in both positive and negative
mode was used. Ionization was achieved using electrospray.
The electrospray source parameters were ﬁxed as follows: the
electrospray capillary voltage was 3.0 kV in negative ionization
mode and 4.0 kV in positive ionization mode. The mass range
ranged from m/z 80 to 1000. The gas temperature was 200◦C in
negative ionization mode and 225◦C in positive ionization mode.
The gas ﬂow was 11 L/min. The nebulizer was set to 35 pisg
(negative) and 45 pisg (positive). The sheath gas temperature was
350◦C, and the sheath gas ﬂow was 12 L/min. The nozzle voltage
was 500 V in both negative and positive mode.
Data Extraction
Sample data were extracted using the MassHunter Proﬁnder
software for peak detection and alignment. Full scan mode was
employed in the mass range of 80–1000 amu. The initial and ﬁnal
retention times were set for data collection.
Multivariate Data Analysis
The resultant data matrices were introduced to the SIMCA-P
11.0 software (Umetrics, Umea, Sweden) for a PCA and PLS-
DA. Prior to PCA, all variables obtained from the data matrix
were mean-centered and scaled to a Pareto variance. PCA, an
unsupervised pattern recognition approach, was used to reduce
the dimension of LC–MS data and disclose intrinsic clustering of
samples. To identify the variables responsible for this separation,
the variable inﬂuence on the projection (VIP) parameter was
used to select variables that most signiﬁcantly contributed to the
discrimination between the metabolomic proﬁles of the control,
ANIT and PLP 80 g/kg groups in a PLS-DA model. VIP is a
weighted sum of squares of the PLS weight, which indicates the
importance of the variable to the entire model. Only variables
with VIP values ≥ 1.0 were selected and used for further data
analysis.
Biomarkers Identification and Pathway
Enrichment Analysis
Compounds with signiﬁcant changes between groups (p-
value < 0.05 and fold-change > 2) were selected as biomarkers.
The potential biomarkers were identiﬁed by an online
biochemical database serviceMETLIN1. The recorded compound
1http://metlin.scripps.edu/
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names and KEGG numbers were subjected to Metaboanalyst2 for
further enrichment and a pathway analysis.
RESULTS
Therapeutic Effects of PLP on
Cholestasis Rats
As shown in Table 1, rats given ANIT displayed remarkable
increases in the ALT and AST levels. Conversely, the serum
levels of ALT and AST were signiﬁcantly reduced when rats were
treated with 80 and 40 g/kg PLP, respectively. The eﬀect of 80 g/kg
PLPwas almost equal to that of UDCA. In addition, the level ALT
but not that of AST was also altered by 20 g/kg PLP. The serum
levels of TBIL, DBIL, ALP, and TBA were markedly enhanced in
ANIT-treated rats compared with the control. UDCA (60 mg/kg)
eﬃciently decreased the serum levels of TBIL, DBIL, and ALP
but weakly decreased the serum level of TBA. Similarly, the levels
of TBIL, DBIL, ALP, and TBA in rats with 80 and 40 g/kg PLP
signiﬁcantly decreased, which coincided with the ﬁndings of our
previous study (Ma et al., 2015).
Histological evaluations provided visual evidence for the
protective eﬀect of PLP on ANIT-induced cholestasis. As shown
2http://www.metaboanalyst.ca/
in Figure 1A, the hepatic tissues in the control group exhibited
normal structures and were free of abnormal morphological
changes in this study. The specimens from ANIT rats showed
acute inﬁltration by polymorphonuclear neutrophils, edema,
sinusoid congestion and hepatic necrosis (Figure 1B). Rats
treated with UDCA and 80 g/kg PLP exhibited mild bile
duct epithelial damage and hepatocyte hydropic degeneration
as well as less neutrophil inﬁltration (Figures 1C,D). The
specimens treated with 40 g/kg PLP exhibited moderate
reductions in inﬂammatory cell inﬁltration and other ANIT-
induced histological damage (Figure 1E). Specimens treated
with 20 g/kg PLP exhibited almost no attenuation liver damage
(portal tract edema, cholangitis, and bile duct epithelial damage;
Figure 1F). These results indicated that 80 g/kg PLP continuously
and signiﬁcantly protected tissues from cholestasis.
Multivariate Statistical Analysis and
Potential Biomarkers Exploration
Principal component analysis was initially used as an
unsupervised statistical method to study diﬀerences in the
metabolome between the control, ANIT and 80 g/kg PLP groups.
A score plot provided a direct image of observational clusters.
As shown in Figures 2A,B, the clustering signiﬁcantly diﬀered
between the control and ANIT or 80 g/kg PLP groups in both
TABLE 1 | Effect of PLP on serum ALT, AST, TBIL, DBIL, ALP, and TBA (n = 6, mean ± SD).
Group ALT (IU/L) AST (IU/L) TBIL (µmol/L) DBIL (µmol/L) ALP (U/L) TBA (µmol/L)
Control 15.78 ± 3.65 3.64 ± 0.81 6.09 ± 1.73 3.51 ± 0.89 59.21 ± 6.55 51.24 ± 6.88
ANIT 103.34 ± 12.18## 36.33 ± 5.61## 35.45 ± 4.97## 29.62 ± 3.45## 111.36 ± 11.95## 606.43 ± 50.98##
UDCA 69.61 ± 10.72∗∗ 23.80 ± 4.74∗∗ 19.53 ± 3.39∗∗ 19.17 ± 4.66∗∗ 89.34 ± 9.14∗∗ 552.05 ± 52.67
PLP 80 g/kg 49.86 ± 10.27∗∗ 15.99 ± 5.32∗∗ 13.49 ± 3.40∗∗ 17.69 ± 2.87∗∗ 65.95 ± 10.39∗∗ 443.39 ± 70.84∗∗
PLP 40 g/kg 60.75 ± 11.69∗∗ 20.89 ± 3.22∗∗ 15.91 ± 3.82∗∗ 23.13 ± 4.04∗∗ 69.44 ± 5.48∗∗ 513.31 ± 66.22∗∗
PLP 20 g/kg 75.02 ± 15.44∗∗ 38.32 ± 9.02 24.56 ± 4.10∗∗ 25.94 ± 4.47∗∗ 72.85 ± 8.16∗∗ 568.80 ± 53.29
Data were expressed as mean ± SD. ∗∗p < 0.01 compared with ANIT group; ##p < 0.01 compared with control group.
FIGURE 1 | Effect of PLP on histological changes in the liver tissue of ANIT-induced rats. Hepatocytes damage was pointed by black arrows. (A) Control;
(B) ANIT; (C) UDCA; (D) PLP 80 g/kg; (E) PLP 40 g/kg; (F) PLP 20/kg. (HE stained, 100× magnification).
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FIGURE 2 | Principal component analysis (PCA) score plot of control, ANIT and PLP 80 g/kg groups. (A) ESI+ model; (B) ESI− model.
positive and negative models. However, the clustering did not
distinguish the ANIT and 80 g/kg PLP groups in PCA. The
results of the PCA indicated that further multivariate statistical
analysis was necessary to discern the relationship among these
three groups.
Partial least-squares discriminant analysis was then applied
to further understand the diﬀerent metabolomics patterns and
identify potential biomarkers showing prominent concentration
changes. As shown in Figures 3A,E, the clustering of the control,
ANIT and 80 g/kg PLP groups could be discriminated in both
positive and negative models. Commonly, the R2X, R2Y, and
Q2 (cum) values provide an estimate of how well the model ﬁts
the data. In our positive model, the R2X, R2Y, and Q2 (cum) of
PLS-DA were 0.750, 0.862, and 0.762, respectively. In addition,
the R2X, R2Y, and Q2 (cum) of PLS-DA were 0.877, 0.856, and
0.740, respectively, in the negative model. These data indicated
that models are of good quality and provide accurate predictions.
Permutation tests with 100 iterations were performed to validate
the model. These tests compared the goodness of ﬁt of the
original model with the goodness of ﬁt of randomly permuted
models. As shown in Figures 3B,F, the validation plots indicated
that the original models were valid. The PLS-DA loading plots
displayed variables that positively correlated with the score plots
(Figures 3C,G). In our results, the loading plot demonstrated
several crucial variables that were far from the center of the
coordinate, indicating that these variables played an important
role in clustering. We marked the top 10 variables with red
box according to their VIP value (Figures 3C,G). Moreover, the
VIP value plot was used to structurally identify these biomarkers
(Figures 3D,H). In this work, a VIP value above 1.0 indicated
by a red box was used as a screening standard to select potential
metabolites.
Identification of Potential Metabolites in
Cholestasis Treatment
Among the 1979 signals detected in the control, ANIT and
80 g/kg PLP groups, variables that signiﬁcantly contributed to
the clustering and discrimination were identiﬁed according to
a threshold of VIP ≥ 1.0. This threshold was obtained after
PLS-DA processing these variables. According to the VIP, 903
variables were selected from the control, ANIT and 80 g/kg PLP
groups as the candidates for fold-changes and ANOVA analyses.
Next, candidates that signiﬁcantly diﬀered among the groups (the
maximum and the minimum) with a p-value below 0.05 and fold-
change exceeding two were identiﬁed as candidate biomarkers
for METLIN and Metaboanalyst identiﬁcation. Twelve potential
biomarkers are summarized in Table 2 with their corresponding
retention time, m/z, formula, and diﬀerences by group.
Pathway Analysis of Cholestasis
Treatment
Detailed analyses of pathways were performed by Metaboanalyst,
which is a free web-based tool that combines results from
powerful pathway enrichment analyses with a topology analysis.
The metabolic pathway analysis revealed that metabolites that
were important for changes in cholestasis were responsible for D-
arginine and D-ornithine metabolism, taurine and hypotaurine
metabolism, porphyrin metabolism, pantothenate and CoA
biosynthesis, primary bile acid biosynthesis, steroid hormone
biosynthesis, arginine and proline metabolism, phenylalanine
metabolism, lysine degradation, etc. (Figures 4A,B). As shown
in Figure 4A, the top ﬁve pathways that impacted the bubble
map were primary bile acid biosynthesis, arginine and proline
metabolism, porphyrin and chlorophyll metabolism, tryptophan
metabolism, and pantothenate and CoA biosynthesis. The top 5%
of metabolite hits in pathways were D-arginine and D-ornithine
metabolism, taurine and hypotaurine metabolism, porphyrin
metabolism, pantothenate and CoA biosynthesis, and primary
bile acid biosynthesis (Figure 4B).
Signaling Networks Associated with the
Pathways of Differentially Expressed
Metabolites
To reveal the interrelatedness among these signaling pathways,
the identiﬁed metabolites and pathways were imported into
the KEGG database to identify interactions. The networks were
primarily related to amino acid metabolism, steroid biosynthesis,
and bile secretion. According to the ﬂow of the pathways,
arginine, phenylalanine, and tryptophan metabolism were
considered to be the up-stream signaling network. Moreover,
glycocholic acid, taurocholic acid, and glycochenodeoxycholic
acid were the direct constituents of bile and served as the
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FIGURE 3 | Partial least-squares discriminant analysis (PLS-DA) of metabolomics data. (A) Score plot in ESI+ model; (B) 100-permutation test in ESI+
model; (C) loading plot in ESI+ model; (D) VIP value plot in ESI+ model; (E) score plot in ESI− model; (F) 100-permutation test in ESI− model; (G) loading plot in
ESI− model; (H) VIP value plot in ESI− model.
down-stream signaling network. In addition, protoporphyrin IX
and 11-deoxycortisol were components of bilirubin and cortisol,
which are also essential substances of bile. Compared with the
ANIT group, the levels of glycocholic acid, taurocholic acid,
glycochenodeoxycholic acid, protoporphyrin IX, pantothenate
and L-tryptophan were markedly down-regulated by 80 g/kg PLP
compared with the control group, as indicated by decreases in
the peak areas. Conversely, L(D)-arginine, 2-phenylacetamide,
4-guanidinobutanoate, and 11-deoxycortisol were signiﬁcantly
up-regulated in the 80 g/kg PLP group (Figure 5).
Western Blotting for Bile Acid
Metabolism Confirmation
To ensure that PLP primarily exerts its eﬀect by regulating
bile acid, we further explored the protein expressions of several
transporters such as BSEP,MRP2, and NTCP. The results showed
that the expression of BSEP, MRP2, and NTCP was markedly
decreased in ANIT-treated rats compared with the control.
Furthermore, treatment with 80 g/kg PLP signiﬁcantly increased
the low expression levels of NTCP, BSEP, and MRP2 in rats.
However, these increases were limited in response to 40 and
20 g/kg PLP (Figures 6A–D).
Potential Metabolite Changes in
Cholestasis in Response to Treatment
with Different Doses of PLP
Phenotype and histopathology analyses indicated that high-dose
PLP (80 g/kg) signiﬁcantly aﬀects cholestasis. Conversely,
only mild changes were observed in the 40 g/kg PLP group
TABLE 2 | Identified metabolites of the serum from different groups.
No R.T. (min) Mass Formula Compounds Ratio changes (significance)
Control/ANIT PLP 80 g/kg/ANIT
1 0.85 174.113 C6H14N4O2 L(D)-Arginine 28.31∗∗ 12.36∗∗
2 0.92 161.104 C7H16NO3 Carnitine 0.84 2.25∗∗
3 1.02 145.083 C5H11N3O2 4-Guanidinobutanoate 2.62∗∗ 2.27∗
4 1.09 219.111 C9H17NO5 Pantothenate 0.45∗∗ 0.71∗∗
5 3.95 204.088 C11H12N2O2 L-Tryptophan 0.98 0.44∗∗
6 4.93 135.068 C8H9NO 2-Phenylacetamide 2.77∗ 14.67∗∗
7 10.22 346.212 C21H30O4 11-Deoxycortisol 3.64∗∗ 1.97
8 10.50 465.306 C26H43NO6 Glycocholic acid 0.0047∗∗ 0.18∗∗
9 10.58 449.311 C26H43NO5 Glycochenodeoxycholic acid 0.013∗∗ 0.31∗∗
10 13.89 515.286 C26H45NO7S Taurocholic acid 0.15∗∗ 0.41∗∗
11 14.52 562.266 C34H34N4O4 Protoporphyrin IX 0.33∗∗ 0.91
12 15.36 399.332 C23H45NO4 L-Palmitoylcarnitine 0.41∗∗ 0.61∗∗
∗∗p < 0.01, ∗p < 0.05 compared with ANIT group.
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FIGURE 4 | Pathway analysis of cholestasis treatment. (A) Bubble map of control, ANIT and PLP 80 g/kg groups in pathway analysis; ① primary bile acid
biosynthesis; ② arginine and proline metabolism; ③ porphyrin and chlorophyll metabolism; ④ tryptophan metabolism; ⑤ pantothenate and CoA biosynthesis;
(B) percentage of pathways among control, ANIT and PLP 80 g/kg comparison.
FIGURE 5 | Signaling networks associated with the differentially expressed metabolites pathways. The red solid box represented as the peak area of PLP
80 g/kg/ANIT > 1; the blue solid box represented as the peak area of PLP 80 g/kg/ANIT < 1.
compared with the ANIT group, and low-dose PLP (20 g/kg)
did not produce marked changes. Therefore, we analyzed
changes in 12 potential metabolites in order to deeply
characterize diﬀerences induced by treatment with various
doses of PLP treatment. Compared with the ANIT group,
80 g/kg PLP signiﬁcantly decreased the levels of glycocholic
acid, taurocholic acid, and glycochenodeoxycholic acid
(Figures 7H–J). However, 40 and 20 g/kg PLP produced
milder changes in these metabolites, which indicated the limited
regulation of bile acid synthesis or secretion (Figures 7H,I).
The levels of L(D)-arginine, 4-guanidinobutanoate and 2-
phenylacetamide increased, whereas the levels of L-tryptophan,
pantothenate and L-palmitoylcarnitine markedly decreased
in response to all three doses of PLP (Figures 7A,C–F,L).
Among the three diﬀerent PLP doses, the changes in
metabolism were most pronounced in response to 80 g/kg
PLP. Other potential metabolites, such as 11-deoxycortisol
and protoporphyrin IX, did not exhibit marked changes in
response to high-dose PLP (Figures 7G,K), and carnitine
exhibited irregular changes in response to the three doses
(Figure 7B).
PCA of Potential Metabolites in
Response to PLP Treatment
To comprehensively analyze the network of metabolic
changes, we further conducted a PCA for the 10 metabolites
included in the signaling network described in section
3.6: L(D)-arginine, 4-guanidinobutanoate, pantothenate, L-
tryptophan, 2-phenylacetamide, 11-deoxycortisol, glycocholic
acid, glycochenodeoxycholic acid, taurocholic acid, and
protoporphyrin IX. As shown in Figure 8A, these metabolites
were divided into three classes, indicated by the green bars.
The control group was included in the ﬁrst class. The second
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FIGURE 6 | Western blotting for bile acid metabolism confirmation. (A) The western blot images of NTCP, BSEP, and MRP2; (B) NTCP protein level in liver
tissue; (C) BSEP protein level in liver tissue; (D) MRP2 protein level in liver tissue. ∗∗p < 0.01, compared with ANIT group; ##p < 0.01, compared with control group.
FIGURE 7 | Potential metabolites changes in cholestasis with different doses of PLP treatment. (A) L(D)-Arginine; (B) carnitine; (C) 4-guanidinobutanoate;
(D) pantothenate; (E) L-tryptophan; (F) 2-phenylacetamide; (G) 11-deoxycortisol; (H) glycocholic acid; (I) glycochenodeoxycholic acid; (J) taurocholic acid; (K)
protoporphyrin IX; (L) L-palmitoylcarnitine. ∗∗p < 0.01, ∗p < 0.05 compared with ANIT group; ##p < 0.01 compared with control group.
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FIGURE 8 | Principal component analysis and heat map of potential
metabolites among PLP treatment. (A) One dimensional score plot of PCA
with potential metabolites. The green bar classified the samples into four
classes. X axis was the number of samples. (B) Heat map of potential
metabolites. Red in gradient presented the increases. Blue in gradient
presented the decreases. Samples with green was control group, samples
with red was ANIT group, samples with blue was PLP 80 g/kg group,
Samples with light brown was PLP 40 g/kg group, samples with purple was
PLP 20 g/kg group.
class contained all 80 g/kg PLP samples and one 40 g/kg
PLP sample. Most of the 40 g/kg PLP samples, all 20 g/kg
PLP samples and the ANIT group were included in the third
class (Figure 8A). The heat map directly indicates changes in
these samples. Speciﬁcally, samples in the control group were
thoroughly divided from samples in the ANIT group, whereas
the distance between the 80 g/kg PLP and ANIT groups was
large. Moreover, 40 g/kg PLP was closer to the ANIT group than
the 80 g/kg PLP group, and the 20 g/kg PLP was the closest to
the ANIT group. This distribution indicated that the metabolites
in the 80 g/kg PLP were more similar to those of the control
group than those of the ANIT group. On the contrary, the
metabolites of the 40 and 20 g/kg PLP groups were more similar
to those of the ANIT group than those of the control group
(Figure 8B).
DISCUSSION
Therapeutic Efficacy and Possible
Mechanism by Which PLP Affects
Cholestasis shown in Previous Research
Cholestasis is the intrahepatic accumulation of potentially toxic
bile acids that occurs in several liver diseases due to the
obstruction or destruction of bile ducts (Serviddio et al., 2014).
Because the outcomes of cholestasis are primary biliary cirrhosis
and sclerosing cholangitis, this disease is invariably considered
diﬃcult to cure (Kim et al., 2000). At present, UDCA is
recognized as a speciﬁc and potent treatment for cholestasis
and is often combined with glucocorticoids (Buryova et al.,
2013). However, the long-term administration of glucocorticoids
may lead to several side eﬀects. Additionally, UDCA is not
consistently eﬃcacious (Arenas et al., 2008). Thus, TCM is
considered to provide a novel approach for treating cholestasis.
Speciﬁcally, PLP is one of the most well known herbs in many
Asian countries, such as China, Korea, and Japan. In the clinic,
it consistently exhibits eﬀects on liver disease, especially at high
doses. In some cases, PLP has been used at doses of up to 200 g per
day, which is ten times the conventional dosage, and continued
to demonstrate positive and stable eﬀects on cholestatic hepatitis
without toxicity (Zhu and Wang, 2012). From a mechanistic
perspective, we previously proved that paeoniﬂorin, the main
active component of PLP, displayed its eﬀect on cholestasis by
reducing the production of ROS and NOX4 (Zhao et al., 2013).
These ﬁndings partially reveal the mechanism of PLP because
cholestasis progression is believed to not only relate to oxidative
stress but also other important factors, such as the dysregulation
of bile acid and inﬂammation. Currently, many studies have
demonstrated that TCM for speciﬁc diseases regulates body
function in various organs and tissues in a network manner
(Li et al., 2007; Li and Zhang, 2013). Thus, metabolomics
might help to identify the mechanism by which PLP aﬀects
cholestasis.
Large Dose Application in Traditional
Chinese Medicine
In this study, the maximum dose of PLP was 80 g/kg·days (as raw
herb), which is high compared with the normal dose of this drug
(15 g/kg·days). In fact, high doses of Chinese herbs have been
widely applied since ancient times, and this approach remains
interesting. For instance, the recorded doses of Gypsum Fibrosum
applied in the Yi Xue Zhong Zhong Can Xi Lu (a medical book
in Qing dynasty) reached up to 300 g per day for relieving fever.
This dose is thirty times the currently used common dose (10 g
per day; Peng, 2003). Furthermore, according to the Li KeMedical
Records, the dose of Radix Aconiti Lateralis Preparata used in Po-
Ge-Jiu-Xin-Decoction was 500 g per day, which is ten times the
regular dosage described in the Chinese Pharmacopeia. Several
studies indicated that Radix Aconiti Lateralis Preparata at this
dose exhibited remarkable therapeutic eﬀects on severe shock and
circulatory failure (Sun, 2007).
Our previous research revealed that high doses of PLP
were not toxic (Wei, 2012). In this study, the weights of rats
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administered 80 g/kg PLP slightly decreased, but the serum
indices and histological data suggested that the livers of rats
in this group were more eﬀectively protected. The eﬀect of
this high dose might be partially related to the chemical
properties of paeoniﬂorin. Paeoniﬂorin protects tissues from
cholestasis, liver ﬁbrosis, acute hepatitis and non-alcoholic
fatty liver disease (Zhao et al., 2013, 2015; Chen et al.,
2015a; Zhang et al., 2015). However, the bioavailability of
paeoniﬂorin is extremely low (Jiang et al., 2012). Therefore,
the application of high doses may increase the level of
paeoniﬂorin in the serum. In addition, we speculate that the
action of high-dose PLP may mechanistically diﬀer from that of
low-dose PLP.
Metabolites Characteristic of PLP
Therapy in Cholestasis
Bile acids are recognized as crucial signaling molecules that
regulate a variety of homeostatic mechanisms (Thomas et al.,
2008). The TBAs in the blood are also reportedly commonly
increased due to the impaired biliary excretion of bile acids
during cholestasis (Chen et al., 2008). In this study, the levels
of several bile acids, such as glycocholic acid, taurocholic acid
and glycochenodeoxycholic acid, were signiﬁcantly increased
after ANIT treatment, which corroborates previous ﬁndings
(Aoki et al., 2011). Notably, glycochenodeoxycholic acid and
glycocholic acid are hydrophobic bile acids. Several studies
have illustrated that the accumulation of several hydrophobic
bile acids during cholestasis might result in hepatotoxicity
via apoptosis and subsequent inﬂammation (Woolbright et al.,
2015). Taurocholic acid is also one of the main bile acids
for intrahepatic cholestasis and is believed to be involved
in the pathogenesis of this disease by provoking a potent
inﬂammatory response (Zhang et al., 2014; Woolbright et al.,
2015). PLP (80 g/kg) markedly down-regulated the levels of
these bile acids in the serum, which suggested that the observed
prevention mechanism is closely related to bile acid synthesis and
secretion.
In addition to bile acids, several representative amino
acids, such as arginine and L-tryptophan, were also detected
in this study. L-Arginine plays important metabolic roles in
the formation of a number of important physiologic factors,
including nitric oxide (NO), urea, creatine and even growth
hormone release (Shao and Hathcock, 2008). A recent study
also revealed that L-arginine protects rats from cholestasis via
NO synthesis and attenuating oxidative stress (Ozsoy et al.,
2011; Tain et al., 2013). L-Tryptophan is the precursor in
serotonin synthesis. Serotonin is synthesized from L-tryptophan
by the enzymes tryptophan hydroxylase and aromatic amino
acid decarboxylase (AADC), and it regulates physiological
functions in the hepatogastrointestinal tract (Lesurtel et al., 2008).
Furthermore, Osawa et al. (2011) reported that L-tryptophan
and its metabolite serotonin are involved in metabolic liver
diseases, such as non-alcoholic fatty liver disease. Accordingly,
we also observed a signiﬁcant decrease in L-tryptophan in
response to treatment with 80 g/kg PLP compared with ANIT
rats.
Possible Signaling Profile Associated
with PLP Prevention in Cholestasis
In this study, bile acid secretion and amino acid metabolism
were recognized as the main signaling network in cholestasis
and PLP treatment (Figure 5). In cholestasis, impaired bile
ﬂow leads to the accumulation of bile acids in the liver,
causing hepatocyte and biliary injury and inﬂammation (Li
and Apte, 2015). The changes in several bile acids, such as
glycocholic acid, taurocholic acid and glycochenodeoxycholic
acid, constitute both the phenotype and cause of the progression
of cholestasis. In our study, we also identiﬁed signiﬁcant
changes in these metabolites. In addition, several proteins
and transporters in hepatocytes are speciﬁcally changed during
cholestasis. Therefore, we measured the protein levels of
BSEP, MRP2, and NTCP. NTCP is the intake pump that
transports bile acid in the blood into hepatocytes. BSEP
and MRP2 are the export pumps that transport bile acids
from hepatocytes into the bile duct. Our data indicated that
ANIT decreases the expression of BSEP, MRP2, and NTCP.
It might be due to preventing the bile acid transporters
in vesicles from being moved to the canalicular membrane.
Moreover, the lower expression of transporters could further
cause accumulation of bile acid. Treatment with PLP was
able to signiﬁcantly increase the lower expression of NTCP,
BSEP, and MRP2 as well as bile acid such as glycocholic acid,
taurocholic acid, and glycochenodeoxycholic acid. The result
implicated that the therapeutic eﬀect of PLP on cholestasis
was probably associated with the bile acid secretion signaling
pathway. Other signaling pathways, such as the generation
of bilirubin and hormonogenesis, might also provide insight
into cholestasis development and prevention. Notably, the
increase in bilirubin is the most hallmark of cholestasis in
both the clinic and laboratory research. We observed that
the level of the upstream metabolite protoporphyrin IX was
also increased in cholestasis. Interestingly, cholestasis might
be relevant to the dysfunction of bilirubin metabolites, which
is the sign of cholestasis. Changes in amino acids were also
detected in our research. In several previous studies, amino
acids were found to play important roles in liver injury and
cholestasis. ROS, a key factor in hepatocyte apoptosis, was
proven to be related to L-tryptophan overexpression (Nocito
et al., 2007). Moreover, sulfur-containing amino acids, such as
S-adenosylmethionine (SAM), are potential agents for cholestasis
treatment. SAM positively regulates GSH, which is the most
important antioxidant molecule in the liver (Jung, 2015). L-
Arginine also eﬃciently treats cholestasis via NO synthesis and
oxidative stress prevention (Ozsoy et al., 2011; Tain et al., 2013).
Furthermore, amino acid metabolism is upstream of the KEGG
pathway maps (01100, metabolic pathways), and several amino
acids, such as L-arginine, L-tryptophan and 2-phenylacetamide,
may ultimately regulate bile acid generation. Although this study
did not conclusively identify the mechanism by which amino
acids change and inﬂuence the downstream signaling pathway
in cholestasis, it did initially depict that changes in amino
acids are an important indicator of and reason for cholestasis
progression.
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CONCLUSION
The serum biochemistry and histopathology data demonstrated
that PLP exerts a signiﬁcant anti-cholestasis eﬀect. Speciﬁcally, a
multivariate analysis detected diﬀerences in the metabolic proﬁle
in response to PLP treatment. Twelve metabolites, including
glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, L-
tryptophan, protoporphyrin IX and pantothenate, were identiﬁed
as markers of cholestasis and PLP treatment. The pathway
and network analyses further indicated that ANIT-induced
cholestasis and PLP treatment primarily aﬀected bile acid
secretion and amino acid metabolism, as indicated by signiﬁcant
changes in associated metabolites. Moreover, the signiﬁcant
changes in bile acid transporters expression also indicated
that bile acid metabolism is involved in the therapeutic
eﬀect of PLP on cholestasis. PCA analysis conﬁrmed the
pharmacological changes induced by PLP at the metabolite
level. According to the result above, the changes in metabolites
and pathways, which are primarily related to bile acid
secretion and likely related to amino acid metabolism, may
partially clarify the therapeutic eﬃcacy of PLP in treating
cholestasis.
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